Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials (Q34337012)

1 August 2017

0 references

1 reference

title

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials (English)

1 reference

1 August 2017

0 references

1 reference

Seidenfeld J

1 reference

1 August 2017

Piper M

1 reference

1 August 2017

Flamm C

1 reference

1 August 2017

Hasselblad V

1 reference

1 August 2017

Armitage JO

1 reference

1 August 2017

Bennett CL

1 reference

1 August 2017

Gordon MS

1 reference

1 August 2017

Lichtin AE

1 reference

1 August 2017

Wade JL 3rd

1 reference

1 August 2017

Woolf S

1 reference

1 August 2017

Aronson N

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Journal of the National Cancer Institute

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

1204-1214

1 reference

Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

21 January 2018

Erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

The red cell transfusion trigger: has a sin of commission now become a sin of omission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Measuring the quality of trials: the quality of quality scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Recommendations for evaluating the validity of quality of life claims for labeling and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Methodologic issues in assessing the quality of life of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Lessons learned from measuring health-related quality of life in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

The use of recombinant human erythropoietin to prevent carboplatin-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Erythropoietin increases hemoglobin in cancer patients during radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.16.1204

21 January 2018

Identifiers

DOI

10.1093/JNCI/93.16.1204

1 reference

1 August 2017

1 reference